Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Andrew Dunn

Senior Biopharma Correspondent

Superluminal Medicines joined the ranks of AI-focused biotechs hauling in megarounds, closing an RA Capital-led $120 million Series A, the startup said Monday.

The new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

FDA tells oncology companies how to run multi-regional cancer trials with a US approval in mind

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Breaking down silos with a new quantitative approach to drug development

Eli Lil­ly in­vests in Su­per­lu­mi­nal's $120M Se­ries A round as AI-fo­cused star­tups eye the clin­ic

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic